指南与共识肝病

无创肝病评估识别门静脉高压:支持AASLD实践指南的系统综述与叙述性综述

Noninvasive liver disease assessment to identify portal hypertension: Systematic and narrative reviews supporting the AASLD Practice Guideline.
指南 / 共识 · Hepatology · 2024-03-15

本系统综述与叙述性综述支持AASLD实践指南,评估无创肝病检测(血液和/或影像)对比HVPG预测慢性肝病患者临床显著门静脉高压(CSPH,HVPG≥10 mmHg)的准确性。共纳入9项研究2492例患者,血液检测准确性较低,影像检测准确性较好但阈值变异大,仅9项研究符合预设纳入标准,研究异质性大,限制确定CSPH的明确阈值。

要点

  • 血液检测APRI敏感性56%、特异性68%,FIB-4敏感性54%、特异性73%,准确性低。
  • 瞬时弹性成像检测肝硬度值在15 kPa时敏感性90%-96%、特异性48%-50%。
  • 瞬时弹性成像在25 kPa时敏感性57%-85%、特异性82%-93%。

核心结论

  • 影像学无创肝病评估检测CSPH的准确性似乎高于血液检测,但仅9项研究符合系统综述预设纳入标准,且研究异质性大、LSM检测CSPH的阈值变异大,限制确定CSPH的明确阈值。

研究设计与样本

  • 系统检索Ovid MEDLINE、Ovid EMBASE、Ovid Cochrane Central Register of Controlled Trials、Ovid Cochrane Database of Systematic Reviews和Scopus,从各数据库建库至2022年4月22日。
  • 仅纳入英文研究,要求单一肝病病因且检查≥50例患者,比较无创检测(血液和/或影像)与HVPG预测慢性肝病患者的CSPH(定义为HVPG≥10 mm Hg),结局为诊断试验准确性指标。
  • 另对不符合系统综述纳入标准的研究进行叙述性综述。
  • 共9项研究2492例患者符合纳入标准。

主要发现

  • 在所研究的肝病和检测CSPH的截断值方面存在显著异质性。
  • 血液检测APRI敏感性56%、特异性68%,FIB-4敏感性54%、特异性73%,准确性低。
  • 影像检测(瞬时弹性成像和剪切波弹性成像检测肝硬度值[LSM])准确性较好但变异大;在15 kPa时,瞬时弹性成像敏感性90%-96%、特异性48%-50%。
  • 在25 kPa时,瞬时弹性成像敏感性57%-85%、特异性82%-93%。
  • 叙述性综述提示影像检测是检测CSPH的最佳可用无创肝病评估;LSM≤15 kPa时CSPH极不可能存在,LSM≥25 kPa时CSPH可能存在。

关键数值与推荐

  • CSPH定义为HVPG≥10 mm Hg。
  • APRI敏感性56%、特异性68%;FIB-4敏感性54%、特异性73%。
  • 瞬时弹性成像在15 kPa时敏感性90%-96%、特异性48%-50%;在25 kPa时敏感性57%-85%、特异性82%-93%。
  • LSM≤15 kPa时CSPH极不可能存在,LSM≥25 kPa时CSPH可能存在。

局限性

  • 仅9项研究符合系统综述预设纳入标准。
  • 研究间存在显著异质性。
  • LSM检测CSPH的截断值存在变异,限制确定CSPH的明确阈值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Portal hypertension is a serious complication of cirrhosis, which leads to life-threatening complications. HVPG, a surrogate of portal pressure, is the reference standard test to assess the severity of portal hypertension. However, since HVPG is limited by its invasiveness and availability, noninvasive liver disease assessments to assess portal pressure, especially clinically significant portal hypertension (CSPH), are needed. APPROACH AND RESULTS: We conducted a systematic review of Ovid MEDLINE(R) Ovid EMBASE, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, and Scopus from each database's inception to April 22, 2022. We included only studies in English that examined ≥50 patients in single liver disease etiologies, which compared noninvasive tests (blood and/or imaging) to HVPG for predicting clinically significant portal hypertension (CSPH; defined as HVPG ≥ 10 mm Hg) in patients with chronic liver disease. Outcomes included measures of diagnostic test accuracy. Additionally, a narrative review of studies not eligible for the systematic review is also provided. Nine studies with 2492 patients met the inclusion criteria. There was substantial heterogeneity with regard to liver disease studied and cutoff values used to detect CSPH. Blood-based tests, including aspartate-to-platelet ratio index (APRI) (56% sensitivity and 68% specificity) and FIB-4 (54% sensitivity and 73% specificity) had low accuracy measures. Imaging-based tests (transient elastography and shear wave elastography detection of liver stiffness measurement [LSM]) had better accuracy but also had substantial variation; at 15 kPa, TE sensitivity was 90%-96% and specificity was 48%-50%, while at 25 kPa, its sensitivity and specificity were 57%-85% and 82%-93%, respectively. The narrative review suggested that imaging-based tests are the best available noninvasive liver disease assessment to detect CSPH; CSPH is highly unlikely to be present at an LSM ≤15 kPa and likely to be present at an LSM ≥25 kPa. CONCLUSIONS: While imaging-based noninvasive liver disease assessment appeared to have higher accuracy than blood-based tests to detect CSPH, only 9 studies fit the a priori established inclusion criteria for the systematic review. In addition, there was substantial study heterogeneity and variation in cutoffs for LSM to detect CSPH, limiting the ability to establish definitive cutoffs to detect CSPH.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Rockey DC, Alsawas M, Duarte-Rojo A, et al. Noninvasive liver disease assessment to identify portal hypertension: Systematic and narrative reviews supporting the AASLD Practice Guideline. Hepatology. 2024. PMID: 38489516. doi:10.1097/HEP.0000000000000841

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。